CIBI363C301: A Randomized, Phase 3 Trial Comparing Efficacy and Safety of TAK-928 and Docetaxel in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (MarsLight-11)

17237CIBI363C301-MARSLIGHT-11OpenCIBI363C301: A Randomized, Phase 3 Trial Comparing Efficacy and Safety of TAK-928 and Docetaxel in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (MarsLight-11)CIBI363C301NCT07217301IndustrialAdultTreatmentIIIGlobalLungJeon, HyeinMedStar Health and GUMC; Medstar Washington Hospital Center : Leila SounnaThoracic/CNS/H&N/ThyroidOncology GroupMHRI Washington Cancer Institute13705Leila SounnaLeila SounnaLeila.Sounna@Medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>